Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | FGFR3 | Direct | 3 | ||||||||
| futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan | FGFR3 | Direct | 3 | ||||||||
| pembrolizumab, belzutifan, lenvatinib | FGFR3 | Direct | 3 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | FGFR3 | Direct | 2 | ||||||||
| bbi-355, erlotinib, futibatinib | FGFR3 | Direct | 2 | ||||||||
| gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a | FGFR3 | Direct | 2 | ||||||||
| lenvatinib, pembrolizumab | FGFR3 | Direct | 2 | ||||||||
| lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate | FGFR3 | Direct | 2 | ||||||||
| mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a | FGFR3 | Direct | 2 | ||||||||
| nintedanib | FGFR3 | Direct | yes | 2 | |||||||
| nintedanib, pembrolizumab | FGFR3 | Direct | 2 | ||||||||
| pazopanib | FGFR3 | Direct | yes | 2 | |||||||
| pembrolizumab, lenvatinib | FGFR3 | Direct | 2 | ||||||||
| pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu | FGFR3 | Direct | 2 | ||||||||
| pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin | FGFR3 | Direct | 2 | ||||||||
| quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery | FGFR3 | Direct | 2 | ||||||||
| biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging | FGFR3 | Direct | 1 | ||||||||
| biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography | FGFR3 | Direct | 1 | ||||||||
| byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab | FGFR3 | Direct | 1 | ||||||||
| erdafitinib | FGFR3 | Direct | yes | 1 | |||||||
| h101, tislelizumab, lenvatinib | FGFR3 | Direct | 1 | ||||||||
| lenvatinib, bevacizumab | FGFR3 | Direct | 1 | ||||||||
| paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) | FGFR3 | Direct | 1 | ||||||||
| pazopanib, 5-fu, oxaliplatin, leukovorin (flo) | FGFR3 | Direct | 1 | ||||||||
| pazopanib, lapatinib | FGFR3 | Direct | 1 | ||||||||
| pazopanib, placebo | FGFR3 | Direct | 1 | ||||||||
| pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin | FGFR3 | Direct | 1 | ||||||||
| pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel | FGFR3 | Direct | 1 | ||||||||
| pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel | FGFR3 | Direct | 1 | ||||||||
| pemigatinib | FGFR3 | Direct | yes | 1 | |||||||
| ponatinib | FGFR3 | Direct | 1 | ||||||||
| selpercatinib | FGFR3 | Direct | 1 | ||||||||
| serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome | FGFR3 | Direct | 1 | ||||||||
| tace, lenvatinib, combined with tislelizumab group | FGFR3 | Direct | 1 | ||||||||
| tace, tislelizumab, lenvatinib | FGFR3 | Direct | 1 | ||||||||
| topotecan, pazopanib | FGFR3 | Direct | 1 | ||||||||
| nintedanib esylate | FGFR3 | Direct | yes | 0 | |||||||
| pazopanib hydrochloride | FGFR3 | Direct | yes | 0 | |||||||
| vandetanib | FGFR3 | Direct | yes | 0 | |||||||
| olaparib | PARP1 | SSL via PARP1 | yes | 1 | |||||||
| docetaxel, thalidomide | BCL2 | SSL via BCL2 | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | BCL2 | SSL via BCL2 | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | VEGFA | SSL via VEGFA | 4 | ||||||||
| ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine | VEGFA | SSL via VEGFA | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | BTK | SSL via BTK | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CDK4 | SSL via CDK4 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CDK6 | SSL via CDK6 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | ERBB2 | SSL via ERBB2 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | MAP2K1 | SSL via MAP2K1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | PIK3CA | SSL via PIK3CA | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | SMO | SSL via SMO | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | WEE1 | SSL via WEE1 | 3 | ||||||||
| afatinib | ERBB2 | SSL via ERBB2 | yes | 3 | |||||||
| amg 193, docetaxel, comparator amg 193 test tablet | BCL2 | SSL via BCL2 | 3 | ||||||||
| bevacizumab | VEGFA | SSL via VEGFA | 3 | ||||||||
| bms-986340, bms-936558-01, docetaxel | BCL2 | SSL via BCL2 | 3 | ||||||||
| mrtx849, pembrolizumab, cetuximab, afatinib | ERBB2 | SSL via ERBB2 | 3 | ||||||||
| trastuzumab emtansine | ERBB2 | SSL via ERBB2 | yes | 3 | |||||||
| tucatinib | ERBB2 | SSL via ERBB2 | yes | 3 | |||||||
| 5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin | VEGFA | SSL via VEGFA | 2 | ||||||||
| 5fu, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin | VEGFA | SSL via VEGFA | 2 | ||||||||
| abemaciclib | CDK4 | SSL via CDK4 | yes | 2 | |||||||
| abemaciclib | CDK6 | SSL via CDK6 | yes | 2 | |||||||
| adavosertib, radiation therapy | WEE1 | SSL via WEE1 | 2 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | ERBB2 | SSL via ERBB2 | 2 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| alvocidib, paclitaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| alvocidib, paclitaxel | CDK4 | SSL via CDK4 | 2 | ||||||||
| alvocidib, paclitaxel | CDK6 | SSL via CDK6 | 2 | ||||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | BCL2 | SSL via BCL2 | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | BTK | SSL via BTK | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | VEGFA | SSL via VEGFA | 2 | ||||||||
| bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis | VEGFA | SSL via VEGFA | 2 | ||||||||
| binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib | CDK4 | SSL via CDK4 | 2 | ||||||||
| binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib | CDK6 | SSL via CDK6 | 2 | ||||||||
| binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| bryostatin 1, paclitaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| btla inhibitor (js004), toripalimab, paclitaxel, cisplatin | BCL2 | SSL via BCL2 | 2 | ||||||||
| capecitabine, docetaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, docetaxel | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, paclitaxel, panitumumab, radiotherapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 | BCL2 | SSL via BCL2 | 2 | ||||||||
| carboplatin, paclitaxel, three-dimensional conformal radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cft1946, trametinib, cetuximab | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cisplatin, paclitaxel, surgical procedure, radiation therapy | BCL2 | SSL via BCL2 | 2 | ||||||||
| cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study | BCL2 | SSL via BCL2 | 2 | ||||||||
| cobimetinib, mehd7945a | MAP2K1 | SSL via MAP2K1 | 2 | ||||||||
| dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg | BCL2 | SSL via BCL2 | 2 | ||||||||
| docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone | BCL2 | SSL via BCL2 | 2 | ||||||||
| durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel | BCL2 | SSL via BCL2 | 2 |